<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>2010 revised Task Force criteria for the diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">2010 revised Task Force criteria for the diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC)</h1>
<div class="graphic"><div class="figure"><div class="ttl">2010 revised Task Force criteria for the diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="85%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Revised Task Force criteria</td> </tr> <tr> <td class="subtitle2_left" colspan="2">I. Global or regional dysfunction and structural alterations*</td> </tr> <tr> <td class="centered" rowspan="3"><strong>Major</strong></td> <td><strong>By 2D echo:</strong> <ul> <li>Regional RV akinesia, dyskinesia, or aneurysm</li> <li><em>and</em> 1 of the following (end diastole): <ul> <li>PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 mm/m<sup>2</sup>)</li> <li>PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 mm/m<sup>2</sup>)</li> <li><em>or</em> fractional area change ≤33%</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By MRI:</strong> <ul> <li>Regional RV akinesia or dyskinesia or dyssynchronous RV contraction</li> <li><em>and</em> 1 of the following: <ul> <li>Ratio of RV end-diastolic volume to BSA ≥110 mL/m<sup>2</sup> (male) or ≥100 mL/m<sup>2</sup> (female)</li> <li><em>or</em> RV ejection fraction ≤40%</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By RV angiography:</strong> <ul> <li>Regional RV akinesia, dyskinesia, or aneurysm</li> </ul> </td> </tr> <tr> <td class="centered" rowspan="2"><strong>Minor</strong></td> <td><strong>By 2D echo:</strong> <ul> <li>Regional RV akinesia or dyskinesia</li> <li><em>and</em> 1 of the following (end diastole): <ul> <li>PLAX RVOT ≥29 to &lt;32 mm (corrected for body size [PLAX/BSA] ≥16 to &lt;19 mm/m<sup>2</sup>)</li> <li>PSAX RVOT ≥32 to &lt;36 mm (corrected for body size [PSAX/BSA] ≥18 to &lt;21 mm/m<sup>2</sup>)</li> <li><em>or</em> fractional area change &gt;33% to ≤40%</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>By MRI:</strong> <ul> <li>Regional RV akinesia or dyskinesia or dyssynchronous RV contraction</li> <li><em>and</em> 1 of the following: <ul> <li>Ratio of RV end-diastolic volume to BSA ≥100 to &lt;110 mL/m<sup>2</sup> (male) or ≥90 to &lt;100 mL/m<sup>2</sup> (female)</li> <li><em>or</em> RV ejection fraction &gt;40% to ≤45%</li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">II. Tissue characterization of wall</td> </tr> <tr> <td class="centered"><strong>Major</strong></td> <td> <ul> <li>Residual myocytes &lt;60% by morphometric analysis (or &lt;50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy</li> </ul> </td> </tr> <tr> <td class="centered"><strong>Minor</strong></td> <td> <ul> <li>Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">III. Repolarization abnormalities</td> </tr> <tr> <td class="centered"><strong>Major</strong></td> <td> <ul> <li>Inverted T waves in right precordial leads (V<sub>1</sub>, V<sub>2</sub>, and V<sub>3</sub>) or beyond in individuals &gt;14 years of age (in the absence of complete right bundle-branch block QRS ≥120 ms)</li> </ul> </td> </tr> <tr> <td class="centered"><strong>Minor</strong></td> <td> <ul> <li>Inverted T waves in leads V<sub>1</sub> and V<sub>2</sub> in individuals &gt;14 years of age (in the absence of complete right bundle-branch block) or in V<sub>4</sub>, V<sub>5</sub>, or V<sub>6</sub></li> <li>Inverted T waves in leads V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, and V<sub>4</sub> in individuals &gt;14 years of age in the presence of complete right bundle-branch block</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">IV. Depolarization/conduction abnormalities</td> </tr> <tr> <td class="centered"><strong>Major</strong></td> <td> <ul> <li>Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V<sub>1</sub> to V<sub>3</sub>)</li> </ul> </td> </tr> <tr> <td class="centered"><strong>Minor</strong></td> <td> <ul> <li>Late potentials by SAECG in ≥1 of the following 3 parameters in the absence of a QRS duration of ≥110 ms on the standard ECG <ul> <li>Filtered QRS duration (fQRS) ≥114 ms</li> <li>Duration of terminal QRS &lt;40 µV (low-amplitude signal duration) ≥38 ms</li> <li>Root-mean-square voltage of terminal 40 ms ≤20 µV</li> </ul> </li> <li>Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R', in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">V. Arrhythmias</td> </tr> <tr> <td class="centered"><strong>Major</strong></td> <td> <ul> <li>Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)</li> </ul> </td> </tr> <tr> <td class="centered"><strong>Minor</strong></td> <td> <ul> <li>Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis</li> <li>&gt;500 ventricular extrasystoles per 24 hours (Holter)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">VI. Family history</td> </tr> <tr> <td class="centered"><strong>Major</strong></td> <td> <ul> <li>ARVC confirmed in a first-degree relative who meets current Task Force criteria</li> <li>ARVC confirmed pathologically at autopsy or surgery in a first-degree relative</li> <li>Identification of a pathogenic mutation<sup>¶</sup> categorized as associated or probably associated with ARVC in the patient under evaluation</li> </ul> </td> </tr> <tr> <td class="centered"><strong>Minor</strong></td> <td> <ul> <li>History of ARVC in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria</li> <li>Premature sudden death (&lt;35 years of age) due to suspected ARVC in a first-degree relative</li> <li>ARVC confirmed pathologically or by current Task Force Criteria in second-degree relative</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Diagnostic terminology for revised criteria:
<ul class="decimal_heading">
<li>Definite diagnosis: 2 major, OR 1 major and 2 minor criteria, OR 4 minor from different categories</li>
<li>Borderline diagnosis: 1 major and 1 minor, OR 3 minor criteria from different categories</li>
<li>Possible diagnosis: 1 major, OR 2 minor criteria from different categories</li>
</ul></div><div class="graphic_footnotes">ARVC: arrhythmogenic right ventricular cardiomyopathy; 2D: 2-dimensional; echo: echocardiography; PLAX: parasternal long-axis view; RVOT: RV outflow tract; BSA: body surface area; PSAX: parasternal short-axis view; MRI: magnetic resonance imaging; SAECG: signal-averaged electrocardiogram; aVF: augmented voltage unipolar left foot lead; aVL: augmented voltage unipolar left arm lead.<br/>
* Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.<br/>
¶ A pathogenic mutation is a DNA alteration associated with ARVC that alters or is expected to alter the encoded protein, is unobserved or rare in a large non-ARVC control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.</div><div class="graphic_reference">Modified with permission from: Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010; 121:1533. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id="graphicVersion">Graphic 58452 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
